73942-87-7

Basic information

• Product Name: 1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one
• Synonyms: Ivabradine Impurity 13;7,8-Dimethoxy-1H-benzo[d]azepin-2(3H)-one;1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one;7,8-dimethoxy-1, 3-dihydro-2H-benzo[d] azepin-2-one;7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one;2H-3-Benzazepin-2-one,1,3-dihydro-7,8-diMethoxy-;1,3-Dihydro-7,8-dimethoxybenzo[d]azepin-2-one;7,8-diMethoxy-2,3-dihydro-1H-3-benzazepin-2-one
• CAS NO: 73942-87-7
• Molecular Formula: C₁₂H₁₃NO₃
• Molecular Weight: 219.24
• EINECS: 1806241-263-5
• Product Categories: Aromatics;Heterocycles;Intermediates
• Mol File: 73942-87-7.mol
• Article Data: 18

Chemical Properties

• Melting Point: 244.0 to 248.0 °C
• Boiling Point: 455.8 °C at 760 mmHg
• Flash Point: 229.5 °C
• Appearance: /
• Density: 1.167
• Vapor Pressure: 1.7E-08mmHg at 25°C
• Refractive Index: 1.546
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: 13.29±0.20(Predicted)
• CAS DataBase Reference: 1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one(73942-87-7)
• EPA Substance Registry System: 1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one(73942-87-7)

Safety Data

• Hazardous Substances Data: 73942-87-7(Hazardous Substances Data)

Usage

Description

1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one is a substituted benzazepinone derivative, which is a type of organic compound with a unique chemical structure. It is characterized by the presence of a benzazepine ring system with two methoxy groups attached to the 7th and 8th positions, and a carbonyl group at the 2nd position. 1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one has potential applications in various fields, particularly in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one is used as a key intermediate in the synthesis of bradycardic agents, which are medications that help to slow down the heart rate. These agents are useful in the treatment of various cardiovascular conditions, such as tachycardia, arrhythmias, and hypertension.
Additionally, 1,3-Dihydro-7,8-dimethoxy-2H-3-benzazepin-2-one is used as a precursor in the development of isoform-selective f-current blockers. These blockers are compounds that selectively inhibit specific isoforms of the fast sodium current (f-current) in cardiac cells, which can be beneficial in the management of certain cardiac arrhythmias.

InChI:InChI=1/C12H13NO3/c1-15-10-5-8-3-4-13-12(14)7-9(8)6-11(10)16-2/h3-6H,7H2,1-2H3,(H,13,14)

Synthetic route

7,8-dimethoxy-3-(4-methoxybenzyl)-1,3-dihydro-2H-3-benzazepin-2-one → 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7)

Conditions	Yield
With trifluoroacetic acid for 8h; Reflux;	97%

N-(2,2-dimethoxy-ethyl)-3,4-dimethoxyphenylacetamide (73954-34-4) → 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7)

Conditions	Yield
With hydrogenchloride; acetic acid In water at 25℃; for 17h;	77.5%
With hydrogenchloride; acetic acid for 17h; Ambient temperature;	75%
With hydrogenchloride; acetic acid In water at 20℃; for 8h;	61.4%

(3,4-Dimethoxyphenyl)acetic acid (93-40-3) → 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7)

Conditions	Yield
Multi-step reaction with 3 steps 1: 81 percent / thionyl chloride / CH2Cl2 / 1 h / Heating 2: triethylamine / CH2Cl2 / 1 h / Ambient temperature 3: 75 percent / glacial acetic acid, conc. HCl / 17 h / Ambient temperature View Scheme
Multi-step reaction with 2 steps 1: 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; benzotriazol-1-ol 2: hydrogenchloride; acetic acid / water View Scheme
Multi-step reaction with 2 steps 1: toluene / 30 h / Reflux 2: hydrogenchloride; sulfuric acid / water / 4 h / 25 - 30 °C / Reflux View Scheme
Multi-step reaction with 3 steps 1: thionyl chloride / dichloromethane 2: triethylamine / dichloromethane 3: hydrogenchloride; acetic acid View Scheme
Multi-step reaction with 2 steps 1: O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; triethylamine / N,N-dimethyl-formamide / 20 °C / Inert atmosphere 2: phosphorus pentaoxide / methanesulfonic acid / 20 °C / Inert atmosphere View Scheme

3,4-dimethoxyphenylacetyl chloride (10313-60-7) → 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7)

Conditions	Yield
Multi-step reaction with 2 steps 1: triethylamine / CH2Cl2 / 1 h / Ambient temperature 2: 75 percent / glacial acetic acid, conc. HCl / 17 h / Ambient temperature View Scheme
Multi-step reaction with 2 steps 1: triethylamine / dichloromethane 2: hydrogenchloride; acetic acid View Scheme

7,8-dimethoxy-3-(4-methoxybenzyl)-1H-3-benzazepine-2,4(3H,5H)-dione → 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7)

Conditions	Yield
Multi-step reaction with 2 steps 1.1: lithium triethylborohydride / tetrahydrofuran / 1.5 h / -78 °C 1.2: -78 - 20 °C 2.1: trifluoroacetic acid / 8 h / Reflux View Scheme

7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepine-2,4-dione (85175-49-1) → 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7)

Conditions	Yield
Multi-step reaction with 3 steps 1.1: potassium carbonate; potassium iodide / acetonitrile / 27.5 h / 80 °C 2.1: lithium triethylborohydride / tetrahydrofuran / 1.5 h / -78 °C 2.2: -78 - 20 °C 3.1: trifluoroacetic acid / 8 h / Reflux View Scheme

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) + (4,5-dimethoxy-2-iodophenyl)methyl bromide (293732-19-1) → 3-(2-iodo-4,5-dimethoxybenzyl)-7,8-dimethoxy-1,3-dihydrobenzo[d]azepin-2-one (1104967-37-4)

Conditions	Yield
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With potassium tert-butylate In N,N-dimethyl-formamide at 0℃; for 0.5h; Stage #2: (4,5-dimethoxy-2-iodophenyl)methyl bromide In N,N-dimethyl-formamide at 20℃; for 2h;	98%

1-bromo-3-chloro-2-methyl propane (6974-77-2) + 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-2-methyl-3-chloro-propane (85176-88-1)

Conditions	Yield
	97.5%
With potassium tert-butylate 1.) DMSO, RT, 30 min, 2.) RT, 30 min; Multistep reaction;

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) + epichlorohydrin (106-89-8) → 1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-2,3-epoxy-propane (85176-49-4)

Conditions	Yield
	94.5%

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) + 1,3-chlorobromopropane (109-70-6) → 3-(3-chloropropyl)-1,3-dihydro-7,8-dimethoxy-2H-3-benzazepine-2-one (85175-59-3)

Conditions	Yield
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With potassium tert-butylate In dimethyl sulfoxide at 25 - 30℃; for 0.5h; Stage #2: 1.3-chlorobromopropane In dimethyl sulfoxide at 15 - 20℃; for 0.5h; Reagent/catalyst; Time; Temperature; Concentration;	89%
	87.3%
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With sodium hydride In N,N-dimethyl-formamide for 0.5h; Stage #2: 1.3-chlorobromopropane In N,N-dimethyl-formamide at 20℃; for 10.5h;	66.5%

2-bromo-2-(2-ethyl)dioxolane (18742-02-4) + 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-(2-[1,3]-dioxolan-2-yl-ethyl)-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one

Conditions	Yield
With sodium hydroxide In 1-methyl-pyrrolidin-2-one; water at 2 - 60℃; for 3h; Product distribution / selectivity;	87%
With potassium carbonate In 1-methyl-pyrrolidin-2-one at 130℃; for 9h; Product distribution / selectivity;	80%

(S)-3-chloro-N-((3,4-dimethoxybicyclo[4.2,0]octa-1(6),2,4-trien-7-yl)methyl)-N-methylpropan-1-amine (1031767-71-1) + 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-(methyl)amino]propyl}-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (1086026-31-4)

Conditions	Yield
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With potassium tert-butylate In dimethyl sulfoxide at 20℃; for 0.5h; Stage #2: (S)-3-chloro-N-((3,4-dimethoxybicyclo[4.2,0]octa-1(6),2,4-trien-7-yl)methyl)-N-methylpropan-1-amine In dimethyl sulfoxide at 20℃;	87%

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) + 4-chloromethyl-1,2-dimethoxy-benzene (7306-46-9) → 3-(3,4-dimethoxybenzyl)-7,8-dimethoxy-1,3-dihydrobenzo[d]azepin-2-one (1104967-46-5)

Conditions	Yield
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With potassium tert-butylate In N,N-dimethyl-formamide at 0℃; for 0.5h; Stage #2: 4-chloromethyl-1,2-dimethoxy-benzene In N,N-dimethyl-formamide at 20℃; for 2h;	86%

2-(3,4-dimethoxyphenyl)-1-iodoethane (64728-23-0) + 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-[2-(3,4-dimethoxyphenyl)ethyl]-7,8-dimethoxy-1,3-dihydrobenzo[d]azepin-2-one (1104967-34-1)

Conditions	Yield
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With potassium tert-butylate In N,N-dimethyl-formamide at 0℃; for 0.5h; Stage #2: 2-(3,4-dimethoxyphenyl)-1-iodoethane In N,N-dimethyl-formamide at 20℃; for 2h;	77%
With potassium tert-butylate In N,N-dimethyl-formamide

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) + N-(tert-butoxycarbonyl)-N-methyl-3-chloropropylamine (114326-14-6) → tert-Butyl [3-(7,8-dimethoxy-2-oxo-1,2-dihydro-3H-3-benzazepin-3-yl)propyl]-methylcarbamate (1232191-37-5)

Conditions	Yield
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With sodium hydride In N,N-dimethyl-formamide; mineral oil at 25℃; for 1h; Stage #2: N-(tert-butoxycarbonyl)-N-methyl-3-chloropropylamine In minreal oil; N,N-dimethyl-formamide at 50℃;	77%
Stage #1: 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one With sodium hydride In N,N-dimethyl-formamide; oil at 25℃; for 1h; Stage #2: N-(tert-butoxycarbonyl)-N-methyl-3-chloropropylamine In N,N-dimethyl-formamide; oil at 50℃;	77%

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) + C16H21NO6S → C27H30N2O6

Conditions	Yield
In toluene at 110 - 130℃; for 6h; Solvent; Temperature;	63.5%

3-chloromethyl-N-[2-(6-methyl-pyrid-2-yl)-ethyl]-pyrrolidine (119919-47-0) + potassium tert-butylate (865-47-4) + 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-[(N-(2-(6-Methyl-pyrid-2-yl)-ethyl)-pyrrolidin-3-yl)methyl]-7,8-dimethoxy-2-oxo-1,3-dihydro-2H-3-benzazepinedihydrochloride

Conditions	Yield
In dimethyl sulfoxide	61%

trans-1,4-dichlorobut-2-ene (110-57-6) + 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → trans-3-(4-chloro-2-butenyl)-7,8-dimethoxy-1,3-dihydro-2H-benzo[d]azepin-2-one

Conditions	Yield
With potassium tert-butylate In dimethyl sulfoxide at 20℃; for 1h;	48%
With potassium tert-butylate In dimethyl sulfoxide at 20℃; Inert atmosphere;

Z-1,4-dichlorobutene (1476-11-5) + 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-((Z)-4-chlorobut-2-en-1-yl)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one (1245568-10-8) + 3,3'-((Z)-but-2-ene-1,4-diyl)bis(7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one) (1245568-12-0)

Conditions	Yield
With potassium tert-butylate In dimethyl sulfoxide at 20℃; Inert atmosphere;	A 30% B 6%

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) + 1-Bromo-2-chloroethane (107-04-0) → 1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-2-chloro-ethane (85176-62-1)

Conditions	Yield
	20%

1-bromo-3-chloro-propan-2-ol (4540-44-7) + 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-(3-Chloro-2-hydroxy-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions	Yield
With potassium tert-butylate 1.) DMSO, RT, 30 min, 2.) RT, 30 min; Multistep reaction;

4-chlorobutyl bromide (6940-78-9) + 7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-(4-Chloro-butyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one (85176-24-5)

Conditions	Yield
With potassium tert-butylate 1.) DMSO, RT, 30 min, 2.) RT, 30 min; Multistep reaction;

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-((E)-4-{[2-(3,4-dimethoxyphenyl)ethyl]methylamino}but-2-enyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions	Yield
Multi-step reaction with 2 steps 1: 48 percent / t-BuOK / dimethylsulfoxide / 1 h / 20 °C 2: 53 percent / Et3N / 5 h / 60 °C View Scheme

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 1-(7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-on-3-yl)-2-chloro-ethane (85176-62-1)

Conditions	Yield
Multi-step reaction with 2 steps 1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min 2: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min View Scheme

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 7,8-Dimethoxy-3-[3-(methyl-phenethyl-amino)-propyl]-1,3-dihydro-benzo[d]azepin-2-one

Conditions	Yield
Multi-step reaction with 2 steps 1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min 2: 2 h / 90 - 95 °C View Scheme

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 7,8-Dimethoxy-3-[3-(methyl-phenethyl-amino)-propyl]-1,3,4,5-tetrahydro-benzo[d]azepin-2-one (92452-47-6)

Conditions	Yield
Multi-step reaction with 3 steps 1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min 2: 2 h / 90 - 95 °C 3: H2 / Pd/C / acetic acid / 10 h / 3750.3 Torr / Ambient temperature View Scheme

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-(3-{[2-(4-Chloro-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions	Yield
Multi-step reaction with 2 steps 1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min 2: 2 h / 90 - 95 °C View Scheme

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-(3-{[2-(4-Hydroxy-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions	Yield
Multi-step reaction with 2 steps 1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min 2: 2 h / 90 - 95 °C View Scheme

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-(3-{[2-(4-Amino-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one (85176-42-7)

Conditions	Yield
Multi-step reaction with 2 steps 1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min 2: 2 h / 90 - 95 °C View Scheme

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 7,8-Dimethoxy-3-(3-{[2-(4-methoxy-phenyl)-ethyl]-methyl-amino}-propyl)-1,3-dihydro-benzo[d]azepin-2-one (85175-70-8)

Conditions	Yield
Multi-step reaction with 2 steps 1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min 2: 2 h / 90 - 95 °C View Scheme

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 1-[7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-on-3-yl]-3-[N-methyl-N-(2-{4-amino-phenyl}-ethyl)-amino]-propane (85175-81-1)

Conditions	Yield
Multi-step reaction with 3 steps 1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min 2: 2 h / 90 - 95 °C 3: H2 / Pd/C / acetic acid / 10 h / 3750.3 Torr / Ambient temperature View Scheme

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-(3-{[2-(4-Dimethylamino-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions	Yield
Multi-step reaction with 2 steps 1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min 2: 2 h / 90 - 95 °C View Scheme

7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one (73942-87-7) → 3-(3-{[2-(3,4-Dichloro-phenyl)-ethyl]-methyl-amino}-propyl)-7,8-dimethoxy-1,3-dihydro-benzo[d]azepin-2-one

Conditions	Yield
Multi-step reaction with 2 steps 1: 1.) potassium tert-butoxide / 1.) DMSO, RT, 30 min, 2.) RT, 30 min 2: 2 h / 90 - 95 °C View Scheme

Upstream product

• 85175-49-1 7,8-dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepine-2,4-dione 
• 10313-60-7 3,4-dimethoxyphenylacetyl chloride 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 
• 73954-34-4 N-(2,2-dimethoxy-ethyl)-3,4-dimethoxyphenylacetamide 

Downstream Products

• 109859-91-8 3[(N-Benzyl-hexahydro-azepin-3-yl)-methyl]-7,8-dimethoxy1,3-dihydro-2H-3-benzazepin-2-one 
• 85175-59-3 3-(3-chloropropyl)-1,3-dihydro-7,8-dimethoxy-2H-3-benzazepine-2-one 
• 1104967-34-1 3-[2-(3,4-dimethoxyphenyl)ethyl]-7,8-dimethoxy-1,3-dihydrobenzo[d]azepin-2-one 
• 1104967-37-4 3-(2-iodo-4,5-dimethoxybenzyl)-7,8-dimethoxy-1,3-dihydrobenzo[d]azepin-2-one 
• 1104967-46-5 3-(3,4-dimethoxybenzyl)-7,8-dimethoxy-1,3-dihydrobenzo[d]azepin-2-one 
• 1086026-31-4 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-(methyl)amino]propyl}-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one 
• 1232191-55-7 3-{3-[[((7R)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl](methyl)amino]propyl}-7,8-dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one 
• 148849-67-6 ivabradine hydrochloride 
• 102226-97-1 N-[3-(7,8-Dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-on-3-yl)-propyl]-3-(phenylamino)-propylamine 
• 102226-96-0 N-[3-(7,8-Dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-on-3-yl)-propyl]-N-(3-phenylaminopropyl)-methylamine 
• 102226-84-6 N-[3-(7,8-Dimethoxy-1,3,4,5-tetrahydro-2H-3-benzazepin-2-on-3-yl)-propyl]-N-(2-phenyloxyethyl)-methylamine 
• 148870-57-9 7,8-dimethoxy-3-[3-iodopropane]-1,3-dihydro-2H-3-benzazepin-2-one 
• 155974-00-8 ivabradine 
• 20925-64-8 7,8-dimethoxy-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepine 

Relevant articles and documents

Design of oxa-spirocyclic PHOX ligands for the asymmetric synthesis of lorcaserin: Via iridium-catalyzed asymmetric hydrogenation

Phosphine-oxazoline (PHOX) ligands are a very important class of privileged ligands in asymmetric catalysis. A series of highly rigid oxa-spiro phosphine-oxazoline (O-SIPHOX) ligands based on O-SPINOL was synthesized efficiently, and their iridium complexes were synthesized by coordination of the O-SIPHOX ligands to [Ir(cod)Cl]2 in the presence of sodium tetrakis-3,5-bis(trifluoromethyl)phenylborate (NaBArF). The cationic iridium complexes showed high reactivity and excellent enantioselectivity in the asymmetric hydrogenation of 1-methylene-tetrahydro-benzo[d]azepin-2-ones (up to 99% yield and up to 99% ee). A key intermediate of the anti-obesity drug lorcaserin could be efficiently synthesized using this protocol.

Benzo aza compound, preparation method and use thereof

Belonging to the field of pharmaceutical chemistry, the invention relates to a benzoazepine compound, a preparation method and application thereof, in particular to the benzoazepine compound, its preparation method and application in the field of treatment of nervous system diseases, especially application in the field of drug addiction related to dopamine D1 and D3 receptors. The benzoazepine compound and pharmacologically acceptable inorganic or organic salts thereof have a structure shown as formula (I). Results of drug experiments carried out by the invention show that the benzoazepine compound and its pharmacologically acceptable inorganic or organic salts have high antagonistic activity on dopamine D1 and D3, can be used as drug leads for further development of dopamine receptor antagonists with good selectivity and high activity, and can be used as potential drugs for treatment of drug addiction by dopamine D1, D3 receptor antagonists. (formula (I)).

PROCESS FOR THE SYNTHESIS OF BENZAZEPINE DERIVATIVES

Process for the synthesis of benzazepine derivatives The invention relates to a process for the synthesis of 7,8-dimethoxy-1,3-dihydro- benzazepin-2-one of formula (II), as well as to a process for the synthesis of compound of formula (I).